MTOR and neoplasm: In a mouse sarcoma model, reduced mechanistic target of rapamycin (mTOR) activity, glycolysis level, and IFN-γ production in T cells are attributed to tumor metabolism and are reversed by immune checkpoint blockade (Chang et al., 2015).